A 45-year-old man was referred for a third opinion regarding vision loss. The vision loss began 2 days after a 4-hour, unremarkable foot surgery for a foot deformity due to type 2 CMTD, an autosomal dominant primary axonal neuropathy. The patient's medical history was otherwise unremarkable. Preoperative 7-item basic metabolic panel and complete blood cell count findings were unremarkable. Postoperatively, his blood chemistry was unremarkable except for hypokalemia, with a potassium level of 3.2 mEq/L (to convert to millimoles per liter, multiply by 1.0). Standard operative medications were delivered, including the following: 2 g of cefazolin, 10 mL of ropivacaine hydrochloride, 0.75%, as a right lower extremity block, 5 mg of midazolam, and 100 μg of fentanyl citrate before induction; 60 mg of lidocaine, 200 mg of propofol, and 50 mg of rocuronium bromide during induction; and 2 mg of cefazolin and 4 mg of ondansetron hydrochloride toward the conclusion of the case. The case was without complication. Postoperatively, the patient's pain was controlled with hydromorphone hydrochloride via a patient-controlled analgesia pump. During his hospital stay, he received nasal mupirocin, docusate sodium, and potassium chloride. The patient was discharged on postoperative day 1 with oxycodone hydrochloride and his usual home medications: α-lipoic acid, 400 mg/d; ascorbic acid, 500 mg/d; coenzyme Q10, 600 mg/d; vitamin B complex daily; and a multivitamin. On ophthalmic examination 29 days after surgery, the patient's best-corrected visual acuity was 20/40 OU while wearing contact lenses with the following prescription: −1.00 + 0.25 × 180 OD and −1.25 + 0.50 × 173 OS. Intraocular pressure measured 15 mm Hg OU. Slitlamp examination results were unremarkable except for significant bilateral posterior cortical cataracts and a Mittendorf dot in the left eye (Figure, A and B). Fundus examination, optical coherence tomography, and fluorescein angiography findings were unremarkable. Follow-up was arranged for cataract extraction evaluation. The patient was seen 16 days later in follow-up, and he described resolution of the vision loss after 1 week of self-initiating the use of an eyedrop containing N-acetylcarnosine, 1%, dosed at 2 drops 4 times daily. His best-corrected visual acuity improved to 20/30 OD and 20/25 OS. Examination revealed complete resolution of the cataracts (Figure, C and D).